Clinical Advances in the Pharmacotherapy of Diabetes
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 20 June 2026 | Viewed by 470
Special Issue Editors
Interests: clinical pharmacy; pharmacotherapy; diabetes; type 2 diabetes; statins; cholesterol; lipids; atherosclerosis; insulin resistance; glucose metabolism; metabolism; risk prediction; cardiovascular epidemiology
Interests: diabetes; diabetic kidney disease; chronic kidney disease; diabetes complications; pharmacotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Therapies and clinical paradigms for the management of diabetes and diabetes-related complications have evolved dramatically in recent years. Evolving evidence from dedicated cardiovascular and kidney outcome trials has rapidly transformed the standard of care management of type 2 diabetes from a traditional “glucocentric” approach to a contemporary comprehensive approach that prioritizes organ protection and achievement and maintenance of weight management goals. The market has also seen a rapid expansion of newly approved pharmacotherapies and diabetes technologies, offering more options than ever for clinicians to tailor their therapeutic approach to the individualized needs of people living with diabetes. This Special Issue, “Clinical Advances in the Pharmacotherapy of Diabetes,” will be featured in the Journal of Clinical Medicine, with Prof. J. Watanabe, Prof. J. Neumiller, and Prof. C. Frazier as Guest Editors.
In this Special Issue, we focus on recent advances in the treatment and management of diabetes and diabetes-related complications and conditions.
Topics of interest include, but are not limited to, the following:
- New and emerging therapies for the treatment of type 2 diabetes;
- Use of therapies and ongoing research on type 1 diabetes delay and prevention;
- Applied use of diabetes technologies (e.g., CGM, AID) in general and special populations and settings;
- Novel paradigms and care models to optimize guideline-directed care;
- Prevention and treatment of diabetes-related complications;
- Real-world effectiveness and safety;
- Pharmacoepidemiology and pharmacovigilance studies;
- Agents for the treatment of diabetes and related conditions in the developmental pipeline (e.g., new and novel insulins, incretin-based therapies);
- Evaluations of adherence, persistence, discontinuation, and concordant effects on outcomes;
- Economic and humanistic evaluations of new diabetes treatments.
Based on your publication record and expertise in this field, we would like to invite you to contribute a paper to this Special Issue; we welcome the submission of research articles and reviews. Original research studies should be appropriately powered for meaningful inference to be concluded. We would additionally appreciate it if you could share this opportunity with any colleagues who may be interested in contributing their work to this Special Issue.
We look forward to receiving your contributions.
Please feel free to reach out with any questions.
Prof. Dr. Jonathan Watanabe
Dr. Joshua J. Neumiller
Guest Editors
Dr. Cheyenne Frazier
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes
- microvascular complications
- macrovascular complications
- diabetes technology
- pharmacoepidemiology
- care delivery
- novel therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
